Correlation between neutrophil-to-lymphocyte ratio and prognosis of patients with lymphoma treated with immune checkpoint inhibitors
Objective To determine the impact of neutrophil-to-lymphocyte ratio(NLR)on the prognosis of patients with lymphoma treated with immune checkpoint inhibitors(ICIs).Methods We retrospectively analyzed 100 patients with lymphoma treated with ICIs from January 2018 to June 2022.The neutrophil and lymphocyte counts before each ICI treatment were collected,and the NLR was measured.The best cut-off value for NLR was obtained with a receiver operating curve.The patients were divided into two groups based on this cut-off value.Kaplan-Meier method and Log-rank test were used for survival analysis.Univariate and multivariate Cox regression models evaluated the relationship between NLR and various clinical features,as well as the efficacy of immunotherapy and progression-free survival(PFS)and overall survival(OS).Results Significant differences in the curative effect were observed between the low and high NLR groups(P=0.041).The PFS in the low NLR group was much better than that in the high NLR group(1-year PFS:70.4％vs 52.6％;2-year PFS:69.1％vs 15.8％;3-year PFS:69.1％vs 15.8％;P=0.001).Similarly,the OS in the low NLR group was much better than that in the high NLR group(1-year OS:85.2％vs 78.9％;2-year OS:81.5％vs 57.9％;3-year OS:81.5％vs 57.9％;P=0.043).Univariate analysis showed that age,age at first immunotherapy,treatment modality,and pretreatment NLR served as prognostic risk factors(P＜0.05).Cox multifactorial analysis found pretreatment NLR and treatment modality to be independent prognostic predictors of PFS(P=0.005,P=0.004).Conclusion Patients with low NLR receiving ICIs treatment have longer PFS and are more likely to benefit from immunosuppressive therapy.Therefore,NLR is a simple and feasible prognostic indicator for patients with lymphoma treated with ICIs.
lymphomaimmune checkpoint inhibitorneutrophil to lymphocyte ratioprognosis
NETL
NSTL
万方数据
